Bellus Health

BELLUS Health (Nasdaq:BLU, TSX:BLU) is a clinical stage biotechnology company developing novel therapeutics for the treatment of refractory chronnic cough and other disorders associated with hypersensitization. The Company’s lead product candidate, BLU-5937, is a highly selective P2X3 antagonist being developed for the treatment of refractory chronic cough, with plans to initiate a Phase 3 program in the second half of 2022.

BELLUS Health (Nasdaq:BLU, TSX:BLU) is a clinical stage biotechnology company developing novel therapeutics for the treatment of refractory chronnic cough and other disorders associated with hypersensitization. The Company’s lead product candidate, BLU-5937, is a highly selective P2X3 antagonist being developed for the treatment of refractory chronic cough, with plans to initiate a Phase 3 program in the second half of 2022022

BELLUS Health (Nasdaq:BLU, TSX:BLU) is a clinical stage biotechnology company developing novel therapeutics for the treatment of refractory chronnic cough and other disorders associated with hypersensitization. The Company’s lead product candidate, BLU-5937, is a highly selective P2X3 antagonist being developed for the treatment of refractory chronic cough, with plans to initiate a Phase 3 program in the second half of 20202

BELLUS Health (Nasdaq:BLU, TSX:BLU) is a clinical stage biotechnology company developing novel therapeutics for the treatment of refractory chronnic cough and other disorders associated with hypersensitization. The Company’s lead product candidate, BLU-5937, is a highly selective P2X3 antagonist being developed for the treatment of refractory chronic cough, with plans to initiate a Phase 3 program in the second half of 220

BELLUS Health (Nasdaq:BLU, TSX:BLU) is a clinical stage biotechnology company developing novel therapeutics for the treatment of refractory chronnic cough and other disorders associated with hypersensitization. The Company’s lead product candidate, BLU-5937, is a highly selective P2X3 antagonist being developed for the treatment of refractory chronic cough, with plans to initiate a Phase 3 program in the second half of 2

BELLUS Health (Nasdaq:BLU, TSX:BLU) is a clinical stage biotechnology company developing novel therapeutics for the treatment of refractory chronnic cough and other disorders associated with hypersensitization. The Company’s lead product candidate, BLU-5937, is a highly selective P2X3 antagonist being developed for the treatment of refractory chronic cough, with plans to initiate a Phase 3 program in the second half of

BELLUS Health (Nasdaq:BLU, TSX:BLU) is a clinical stage biotechnology company developing novel therapeutics for the treatment of refractory chronnic cough and other disorders associated with hypersensitization. The Company’s lead product candidate, BLU-5937, is a highly selective P2X3 antagonist being developed for the treatment of refractory chronic cough, with plans to initiate a Phase 3 program in the second half oof

BELLUS Health (Nasdaq:BLU, TSX:BLU) is a clinical stage biotechnology company developing novel therapeutics for the treatment of refractory chronnic cough and other disorders associated with hypersensitization. The Company’s lead product candidate, BLU-5937, is a highly selective P2X3 antagonist being developed for the treatment of refractory chronic cough, with plans to initiate a Phase 3 program in the second half o

BELLUS Health (Nasdaq:BLU, TSX:BLU) is a clinical stage biotechnology company developing novel therapeutics for the treatment of refractory chronnic cough and other disorders associated with hypersensitization. The Company’s lead product candidate, BLU-5937, is a highly selective P2X3 antagonist being developed for the treatment of refractory chronic cough, with plans to initiate a Phase 3 program in the second half

BELLUS Health (Nasdaq:BLU, TSX:BLU) is a clinical stage biotechnology company developing novel therapeutics for the treatment of refractory chronnic cough and other disorders associated with hypersensitization. The Company’s lead product candidate, BLU-5937, is a highly selective P2X3 antagonist being developed for the treatment of refractory chronic cough, with plans to initiate a Phase 3 program in the second halhalf

BELLUS Health (Nasdaq:BLU, TSX:BLU) is a clinical stage biotechnology company developing novel therapeutics for the treatment of refractory chronnic cough and other disorders associated with hypersensitization. The Company’s lead product candidate, BLU-5937, is a highly selective P2X3 antagonist being developed for the treatment of refractory chronic cough, with plans to initiate a Phase 3 program in the second hahal

BELLUS Health (Nasdaq:BLU, TSX:BLU) is a clinical stage biotechnology company developing novel therapeutics for the treatment of refractory chronnic cough and other disorders associated with hypersensitization. The Company’s lead product candidate, BLU-5937, is a highly selective P2X3 antagonist being developed for the treatment of refractory chronic cough, with plans to initiate a Phase 3 program in the second hha

BELLUS Health (Nasdaq:BLU, TSX:BLU) is a clinical stage biotechnology company developing novel therapeutics for the treatment of refractory chronnic cough and other disorders associated with hypersensitization. The Company’s lead product candidate, BLU-5937, is a highly selective P2X3 antagonist being developed for the treatment of refractory chronic cough, with plans to initiate a Phase 3 program in the second h

BELLUS Health (Nasdaq:BLU, TSX:BLU) is a clinical stage biotechnology company developing novel therapeutics for the treatment of refractory chronnic cough and other disorders associated with hypersensitization. The Company’s lead product candidate, BLU-5937, is a highly selective P2X3 antagonist being developed for the treatment of refractory chronic cough, with plans to initiate a Phase 3 program in the second

BELLUS Health (Nasdaq:BLU, TSX:BLU) is a clinical stage biotechnology company developing novel therapeutics for the treatment of refractory chronnic cough and other disorders associated with hypersensitization. The Company’s lead product candidate, BLU-5937, is a highly selective P2X3 antagonist being developed for the treatment of refractory chronic cough, with plans to initiate a Phase 3 program in the seconsecond

BELLUS Health (Nasdaq:BLU, TSX:BLU) is a clinical stage biotechnology company developing novel therapeutics for the treatment of refractory chronnic cough and other disorders associated with hypersensitization. The Company’s lead product candidate, BLU-5937, is a highly selective P2X3 antagonist being developed for the treatment of refractory chronic cough, with plans to initiate a Phase 3 program in the secosecon

BELLUS Health (Nasdaq:BLU, TSX:BLU) is a clinical stage biotechnology company developing novel therapeutics for the treatment of refractory chronnic cough and other disorders associated with hypersensitization. The Company’s lead product candidate, BLU-5937, is a highly selective P2X3 antagonist being developed for the treatment of refractory chronic cough, with plans to initiate a Phase 3 program in the secseco

BELLUS Health (Nasdaq:BLU, TSX:BLU) is a clinical stage biotechnology company developing novel therapeutics for the treatment of refractory chronnic cough and other disorders associated with hypersensitization. The Company’s lead product candidate, BLU-5937, is a highly selective P2X3 antagonist being developed for the treatment of refractory chronic cough, with plans to initiate a Phase 3 program in the sesec

BELLUS Health (Nasdaq:BLU, TSX:BLU) is a clinical stage biotechnology company developing novel therapeutics for the treatment of refractory chronnic cough and other disorders associated with hypersensitization. The Company’s lead product candidate, BLU-5937, is a highly selective P2X3 antagonist being developed for the treatment of refractory chronic cough, with plans to initiate a Phase 3 program in the sse